

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2007 (25.01.2007)

PCT

(10) International Publication Number
WO 2007/010546 A1

(51) International Patent Classification:

C07C 69/78 (2006.01) **A61P 3/06** (2006.01)
A61K 31/235 (2006.01) **A61Q 5/00** (2006.01)
A61K 31/24 (2006.01) **A61Q 19/00** (2006.01)
C07C 205/57 (2006.01) **A61Q 99/00** (2006.01)
A61K 8/37 (2006.01)

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/IN2005/000318

(22) International Filing Date:

19 September 2005 (19.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

864/MUM/2005 21 July 2005 (21.07.2005) IN

(71) Applicant (for all designated States except US): **RELIANCE LIFE SCIENCES PVT LTD** [IN/IN]; DAKC, LSC, Plot No. R-282, TTC Area of MIDC, Rabale, Navi Mumbai 400 701, Maharashtra (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **UPADHYAY, Shakti** [IN/IN]; Drug Discovery & Development, Reliance Life Sciences Pvt. Ltd, DAKC, LSC, Plot no R-282, TTC Area of MIDC, Rabale, Navi Mumbai 400 701 (IN). **YADAV, Raman** [IN/IN]; Drug Discovery & Development, Reliance Life Sciences Pvt. Ltd, DAKC, LSC, Plot no R-282, TTC Area of MIDC, Rabale, Navi Mumbai 400 701 (IN). **GANGAN, Vijay** [IN/IN]; Drug Discovery & Development, Reliance Life Sciences Pvt. Ltd, DAKC, LSC, Plot no R-282, TTC Area of MIDC, Rabale, Navi Mumbai 400 701 (IN). **KANEKAR, Yogesh** [IN/IN]; Drug Discovery & Development, Reliance Life Sciences Pvt. Ltd, DAKC, LSC, Plot no R-282, TTC Area of MIDC, Rabale, Navi Mumbai 400 701 (IN).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR TREATMENT OF LIPASE-MEDIATED DISEASES

(57) Abstract: Novel benzoquinone-derived compounds and polymorphs and prodrugs thereof, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of such compounds, polymorphs, prodrugs and isomers are provided. Process for preparation of compounds of the invention and pharmaceutical compositions containing such compounds and active polymorphs, prodrugs, isomers or pharmaceutically acceptable salts, esters thereof and their use for reducing or inhibiting activity of lipase gene family for treatment, amelioration or prevention of lipase gene family mediated diseases and conditions including overweight, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, diabetes, atherosclerosis, other cardiovascular diseases, metabolic syndromes, metabolic disorders, skin, hair, and cosmetic are provided.

WO 2007/010546 A1